About Sensius
Sensius is a company based in Rotterdam (Netherlands) founded in 2015 by Paul Van Den Biggelaar and Peter Van Paassen. Sensius has raised $24.78 million across 6 funding rounds from investors including European Union, EIC Fund and UNIIQ. Sensius offers products and services including Thermotherapy System, Focuscore Applicator, and Head and Neck Cancer Applicator. Sensius operates in a competitive market with competitors including ElmediX, Siva Therapeutics, MagHeals, MagForce and Verthermia, among others.
- Headquarter Rotterdam, Netherlands
- Founders Paul Van Den Biggelaar, Peter Van Paassen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.78 M (USD)
in 6 rounds
-
Latest Funding Round
$17.25 M (USD), Series B
Jun 19, 2025
-
Investors
European Union
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sensius
Sensius offers a comprehensive portfolio of products and services, including Thermotherapy System, Focuscore Applicator, and Head and Neck Cancer Applicator.
Device for targeted tumor heating in cancer therapy
Generates microwaves for precise thermotherapy treatments
Applies heat to head and neck tumors during therapy
People of Sensius
Unlock access to complete
Unlock access to complete
Funding Insights of Sensius
Sensius has successfully raised a total of $24.78M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $17.25 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sensius
Sensius has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, EIC Fund and UNIIQ.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
UNIIQ is focused on funding early-stage innovations in South Holland.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Sensius
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sensius
Investment portfolio details for Sensius
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sensius
Detailed financials for Sensius
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sensius Comparisons
Peer comparison for Sensius
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sensius
Sensius operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ElmediX, Siva Therapeutics, MagHeals, MagForce and Verthermia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of the device for treating pancreatic cancer
|
|
| Locked | Locked | Locked |
Gold nanoparticle hyperthermia technology for cancer therapy is developed.
|
|
| Locked | Locked | Locked |
Magnetic hyperthermia devices for non-invasive cancer treatment are provided.
|
|
| Locked | Locked | Locked |
Medical devices utilizing magnetic hyperthermia for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer treatment is enabled through a hyperthermia therapeutic platform.
|
Detailed competitors of Sensius
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sensius
Complete news archive for Sensius
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sensius
Sensius was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Sensius is headquartered in Rotterdam, Netherlands. It is registered at Rotterdam, South Holland, Netherlands.
Paul Van Den Biggelaar is the current CEO of Sensius. They have also founded this company.
Sensius is a funded company, having raised a total of $24.78M across 6 funding rounds to date.
Developer of a hyperthermia system for cancer treatment. This system uses thermotherapy, a controlled heating process, to target tumors while preserving surrounding healthy tissue. The technology is designed to be integrated with existing radiotherapy workflows, offering improved clinical outcomes and enhanced quality of life for patients. The system is currently in development, with prototypes undergoing clinical trials. Future applications are planned for various cancer types.
Sensius's top competitors include MagHeals, Siva Therapeutics and ElmediX.
Sensius offers Thermotherapy System, Focuscore Applicator, and Head and Neck Cancer Applicator.
Sensius has 5 investors. Key investors include European Union, EIC Fund, UNIIQ, GrayBella Capital, and UCEA.